

13<sup>th</sup> November, 2020

To,  
The Manager,  
Dept. of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001  
Scrip Code: 511509

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Advertisement in Newspapers-Reg.**

With reference to the subject cited above we are herewith enclosing the copies of advertisement issued in newspapers on 13<sup>th</sup> November, 2020 in “**Financial Express**” in English Language and in “**Nava Telangana**” in Telugu Language, with respect to publication of Un-Audited Consolidated Financial Results for the second quarter and Half year ended 30<sup>th</sup> September, 2020.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

**For Vivo Bio Tech Limited**

*A. Karthik*

**A.Karthik**  
Company Secretary



### Stimulus 3.0: Now, guaranteed credit for large firms in 27 sectors

The government has already earmarked a corpus of ₹41,600 crore over the current and the next three financial years to implement the ECLGS.

Unlike in the ECLGS 1.0, there is no turnover limit set for the companies to tap the scheme. Their accounts must have been SMA-0 (where the delay in repayment ranges between one and 30 days) as of February 29, 2020. Interest rates under both the versions are capped at 9.25% for banks and other financial institutions, and 14% for NBFCs. However, instead of four years, the tenor of loans to be provided under the ECLGS 2.0 is five years, including a moratorium of one year on principle repayment.

“ECLGS 2.0 to provide much-needed relief to stressed sectors by helping entities sustain employment and meet liabilities. It will also benefit MSME sector which provides goods and services to eligible entities,” the finance minister said.

Loan growth has been faltering in recent months. According to the latest RBI data, non-food bank credit growth decelerated to 5.8% on year in September from 8.1% a year before.

Loans of ₹2.05 lakh crore have been sanctioned so far under the ECLGS since its roll-out on June 1 to 61 lakh borrowers. Of this, an amount of ₹1.52 lakh crore has been disbursed.

Under ECLGS 1.0, announced as part of the government’s ₹21 lakh-crore relief package in May, the Centre has pledged full guarantee for up to 20% extra, collateral-free working capital loans, subject to the ₹3-lakh-crore limit. While this scheme was initially meant for only MSMEs, the Centre, in August, decided to relax the eligibility criteria to cover professionals and enable a wider pool of businesses to benefit from it.

Still, as part of its expanded coverage, companies with an annual turnover limit of only up to ₹250 crore are eligible to tap ECLGS 1.0. Even individuals such as doctors, chartered accountants, lawyers, etc, who wish to take loans for professional purposes, are covered. Similarly, eligible businesses with only up to ₹50 crore outstanding as of February 29 can avail of the additional guaranteed loans.

### Tax sops announced to help developers, woo homebuyers

He further said while the move will benefit most projects, the limit of ₹2 crore may make it not so attractive for a place like Mumbai or Delhi where prices are high. “While you will get properties for ₹2 crore in the suburbs, in central and south Mumbai and in Delhi the properties of ₹2 crore will be a rarity. Also, prices have fallen more in the high-end markets compared with the lower segments of the market,” he said.

Motilal Oswal Real Estate CEO Sharad Mittal said, with the softening of prices across markets, this price difference was in excess of 10% in some cases which kept some of the home buyers at bay. “While the move of increasing the differential from 10% to 20% will certainly help the real estate sector liquidate inventory as it brings more homebuyers to the fore, the impact will be limited as unsold inventory is highest in Mumbai

and NCR markets where property values are higher than ₹2 crore,” he said.

There is another reason that the measure may have limited scope. Lias Foras founder and MD Pankaj Kapoor explained that there are not too many regions where circle rates are higher than the prevailing market rate. “In most regions, the circle rates have been lower than the prevailing market rate. However, this provision provides a scope to the developers to reduce prices. This may also open up the scope of absorbing some black money in real estate,” he said.

Credai national president Satish Magar said while the industry had asked for a complete abandonment of 43CA, the increase to 20% is also a good enough move. “If someone wants to sell below the ready reckoner price, he has a margin of 20% to sell now. Being in an extraordinary situation if someone wants to liquidate their inventory, this is a good measure for that,” he said.

Sunteck Realty CMD Kamal Khetan said, “Property value in many parts of India has already gone down below the ready reckoner rates. The move to hike the differential to 20% will help developers offload the inventory and homebuyers to proactively buy properties without any tax liability.”

Naredco president (national) and Assocham president Niranjan Hiranandani said the cap of ₹2 crore will result in most projects in metro cities not being able to take advantage of this. “It has consistently been pointed out by industry bodies that price points in metro cities need to be kept in mind while offering any such relaxation,” he said.

Meanwhile, partner at Nangia Andersen LLP Sandeep Jhunjhunwala pointed out that by limiting the total value of consideration for residential units to ₹2 crore will give respite only to the middle income group feeling the heat of cash and liquidity crunch in the pandemic-ridden environment.

### Emphasis on job creation for the low-skilled

Under the PM Garib Kalyan Rozgar Yojana (PMGKRY), a scheme that dovetails various rural-centric schemes such as MGNREGS and launched in June mainly to provide livelihood opportunities to returnee migrant workers in 116 districts, the government will provide an additional ₹10,000 crore this year. Apart from MGNREGS, the money would be spent on Pradhan Mantri Gram Sadak Yojana (PMGSY). “This will accelerate the growth of the rural economy,” finance minister Nirmala Sitharaman said.

Of the ₹50,000 crore allocated under PMGKRY, ₹37,543 crore has already been spent, the FM said. Under PMGSY, ₹19,500 crore was allocated in the Budget for 2020-21.

For encouraging creation of formal employment, the Centre will bear the entire 24% contribution of both the employers and the employees, towards EPF for new employees earning less than ₹15,000 a month in estab-

### From the Front Page

lishments having less than 1,000 employees and bear the employees’ contribution of 12% in establishments with more than 1,000 employees.

The new scheme, Aatmanirbhar Bharat Rozgar Yojana, will remain operational till June next year and the subsidy under the scheme can be availed for two years. The estimated subsidy outgo under the scheme for the current fiscal would be around ₹6,000 crore. Overall, it could go up to ₹36,000 crore. “This will encourage formal employment,” said former Central Provident Fund commissioner KK Jalan.

New employees would mean both those who will be entering into formal employment for the first time with freshly allotted Aadhaar-seeded universal account number (UAN) by the EPFO as well as those who would be rejoining into formal

employment (already having been UAN allotted) after losing job during the pandemic period between March and September, 2020, within ₹15,000 monthly salary threshold.

Employers will have to add at least two new employees in their establishments if they have a total workforce of 50 and five, in case they have the strength of more than 50 employees to be eligible to avail the offer. “Around 99.1% of the formal employment will be able to avail benefits under the scheme,” the FM said.

“The EPF subsidy gives its low wage aspect (<₹15,000) will most likely lead to creation of low-skilled jobs and in that sense, low skilled and low paying jobs are likely to be created,” XLRI professor KR Shyam Sundar said.

### Stimulus of barely

### 2% of GDP offset by spending rejig

Since all stimulus schemes are demand-driven and spending decisions are prone to bureaucratic evaluations and vetting, the actual stimulus spending could turn out to be less than envisaged. For schemes that are to run for over a year (the five-year PLSI scheme to boost manufacturing and exports, for instance), the remainder of the current fiscal is unlikely to witness spending that corresponds to a full year.

Sitharaman on Thursday said the steps taken so far, including the monetary measures of RBI to boost credit flows and systemic liquidity, are worth close to ₹30 lakh crore or 1.5% of GDP. The government’s steps alone have been worth ₹17.2 lakh crore or 0.9% of GDP, she said. But that involves many existing schemes, whose costs had been

included in the original Budget projections. Schemes that are to run for several years and private investments/spending that the government intends to spur and facilitate via assorted incentives are also part of the government’s estimate of the stimulus.

A ₹65,000-crore additional outlay for fertiliser subsidy, over and above ₹71,309 crore budgeted, is the largest budgetary component of the stimulus 3.0. This will ensure that entire subsidy dues to the fertiliser companies, including ₹48,000-crore arrears, will be cleared in the current fiscal. This is an unprecedented step, as a major part of subsidy for any year used to be released in the subsequent year/s, leading to liquidity problems for the fertiliser industry and shortage of fertilisers in many parts of the country. Given the agitation over the farm Bills, and the fact that the agriculture sector is proving to be silver lining on the cloud of

economic slump, the government can’t afford paucity of fertilisers in the rabi season.

The government still has some room for unveiling more stimuli, even without altering the estimated budget size for the year or the enhanced gross borrowing limit of Rs 12 lakh crore. Analysts have projected the Centre’s fiscal deficit in FY21 to be 7-8% of GDP compared with 3.5% budgeted. A big dose of stimulus will require the deficit to widen even beyond this level. Apparently, the government doesn’t want that to happen and prefers to keep stimulus within a certain limit.

Batting for ‘additional’ fiscal spending, chief economic adviser Krishnamurthy Subramanian said recently: “At this juncture, returning to the high-growth trajectory gets priority over fiscal balance. As such, even in the past, a rating downgrade didn’t quite impact India’s financial system.”

MERCANTILE VENTURES LIMITED													
CIN: L65191TN1985PLC037309													
Regd. Office: 88, Mount Road, Guindy, Chennai - 600 032 Tel: 044-40432205 Email: admin@mercantileventures.co.in www.mercantileventures.co.in													
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2020													
(₹ in lakhs)													
Sl. No.	Particulars	Standalone						Consolidated					
		Quarter ended 30.09.2020 Unaudited	Quarter ended 30.06.2020 Unaudited	Quarter ended 30.09.2019 Unaudited	Half year ended 30.09.2020 Unaudited	Half year ended 30.09.2019 Unaudited	Year ended 31.03.2020 Audited	Quarter ended 30.09.2020 Unaudited	Quarter ended 30.06.2020 Unaudited	Quarter ended 30.09.2019 Unaudited	Half year ended 30.09.2020 Unaudited	Half year ended 30.09.2019 Unaudited	Year ended 31.03.2020 Audited
1	Total income from operations	392.56	407.26	428.63	799.82	762.27	1606.10	924.88	943.44	933.85	1,868.32	1852.46	3823.94
2	Net Profit/(Loss) for the period before tax, exceptional and/or extraordinary items	287.95	141.74	189.78	429.69	365.81	686.80	283.72	125.30	194.14	409.02	383.98	839.64
3	Net Profit/(Loss) for the period before tax, after exceptional and/or extraordinary items	287.95	141.74	189.78	429.69	365.81	686.80	283.72	125.30	194.14	409.02	383.98	839.64
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	215.48	106.07	148.92	321.55	277.55	853.74	205.91	86.30	155.74	292.21	294.59	1136.59
5	Total Comprehensive Income for the period Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	646.16	363.16	95.04	1,009.32	250.64	(142.73)	884.64	365.29	160.39	1,249.93	385.12	(33.84)
6	Equity Share Capital	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82	11191.82
	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)												
	- Basic:	0.19	0.09	0.13	0.29	0.25	0.76	0.22	0.12	0.15	0.34	0.28	0.84
	- Diluted:	0.19	0.09	0.13	0.29	0.25	0.76	0.22	0.12	0.15	0.34	0.28	0.84

**Notes:**

- The above is an extract of the detailed format of Standalone and consolidated Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Statutory Auditors have carried out a limited review of the accounts for the quarter and half year ended 30 September 2020 and have issued an unmodified report.
- The full format of the quarterly financial results are available on the websites of Stock Exchange at www.bseindia.com and also on Company's website www.mercantileventures.co.in.

For Mercantile Ventures Limited

E N Rangaswami  
Whole-time Director  
DIN: 06463753

VIVO BIO TECH LIMITED				
CIN: L6593TG1987PLC007163				
# 8-2-672/ 5 & 6, 3rd Floor, Ilyas Mohammed Khan Estate, Road No. 1, Banjara Hills, Hyderabad - 500034, Telangana, India. Ph. No.: 040 - 2331 3288				
E-mail: investors@vivobio.com / Website: www.vivobio.com				
EXTRACT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS OF VIVO BIO TECH LIMITED FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020				
Rs. In Lacs except per equity share data				
Sl. No.	Particulars	QTR ENDED 30.09.2020	HALF YEAR ENDED 30.09.2020	QTR ENDED 30.09.2019
		Un-Audited	Un-Audited	Un-Audited
1	Total Income from Operations	1466.53	2381.93	1357.37
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	364.86	456.70	168.25
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	364.86	456.70	168.25
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	210.43	308.19	233.41
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	210.43	308.19	233.41
6	Equity Share Capital	1288.75	1288.75	1275.05
7	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)*			
	i. Basic	1.63	2.39	1.83
	ii. Diluted	1.63	2.39	1.83

**Notes:**

- The above Un-Audited Financial Results are reviewed and recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 11th November, 2020.
- The Consolidated Results include results of all subsidiaries.
- The above is an Extract of the detailed format of Quarterly Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com
- Standalone Financial Information (Un-Audited)

Rs. In Lacs				
Sl. No.	Particulars	QTR ENDED 30.09.2020	HALF YEAR ENDED 30.09.2020	QTR ENDED 30.09.2019
		Un-Audited	Un-Audited	Un-Audited
1.	Total Income	1466.53	2381.93	1357.37
2.	Profit before Tax	369.89	461.73	168.25
3.	Profit for the Period	215.45	313.21	233.41

For Vivo Bio Tech Limited  
Sd/-  
M. Kalyan Ram  
Whole Time Director  
DIN: 02012580

Date: 11<sup>th</sup> November, 2020  
Place: Hyderabad

AMRUTANJAN HEALTH CARE LIMITED						
REGD. OFFICE: New No.103 (Old No.42-45), Luz Church Road, Mylapore, Chennai-600 004						
email id: investors@amrutanjan.com   website: www.amrutanjan.com   CIN No: L24231TN1936PLC000017						
EXTRACT FROM THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 <sup>TH</sup> SEP 2020						
						
(₹ in lakhs except EPS)						
Particulars	Quarter Ended		Period Ended		Year Ended	
	30-Sep-20	30-Jun-20	30-Sep-19	30-Sep-20	30-Sep-19	31-Mar-20
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	9,211.17	4,661.85	7,480.77	13,873.02	11,940.36	26,147.67
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	3,138.87	866.12	1,212.27	4,004.99	1,121.71	3,445.39
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	3,138.87	866.12	1,212.27	4,004.99	1,121.71	3,445.39
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	2,354.88	642.72	840.34	2,997.60	769.86	2,508.33
Total Comprehensive Income for the period [(comprising Profit / (loss) for the period (after tax) and Other comprehensive income (after tax)]	2,371.50	639.85	808.86	3,011.35	735.95	2,478.96
Equity Share Capital	292.31	292.31	292.31	292.31	292.31	292.31
Reserves (excluding Revaluation Reserve)	15,650.25	15,650.25	14,281.32	15,650.25	14,281.32	15,650.25
	(As on 31-03-2020)	(As on 31-03-2020)	(As on 31-03-2019)	(As on 31-03-2020)	(As on 31-03-2019)	(As on 31-03-2020)
Earnings Per Share (₹.1/- each)						
Basic & Diluted	8.06 (not annualised)	2.20 (not annualised)	2.87 (not annualised)	10.25 (not annualised)	2.63 (not annualised)	8.58 (annualised)

**Notes:**

- The above is an extract of the detailed format of Quarterly and six months Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and six months Financial Results are available on the Stock Exchange websites www.bseindia.com and www.nseindia.com and on the Company's website www.amrutanjan.com.
- The above financial results for the quarter and six months ended 30 September 2020 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12 November 2020. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.
- The financial results have been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS), 34 - 'Interim Financial Reporting' as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961, as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the half year ended September 30, 2019 and re-measured its deferred tax assets basis the rate prescribed in the said section. The impact of above mentioned change was recognised in the statement of profit and loss for the half year ended September 30, 2019 and for the year ended March 31, 2020.
- In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The Company has considered internal and external information while finalizing various estimates in relation to its financial results captions upto the date of approval of the financial results by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID-19 situation evolves in India and globally. The Company will continue to closely monitor any material changes to future economic conditions.

For Amrutanjan Health Care Limited  
-s/d  
S. Sambhu Prasad  
Chairman & Managing Director

GRP Limited						
CIN : L25191G1974PLC002555						
Registered Office : Plot No.8, GIDC Estate, Ankleshwar - 393 002 Dist. Bharuch, Gujarat						
Tel. No.: 022 67082600 / 2500, Fax : 022 67082599, e-mail id : investor.relations@grpweb.com, website: www.grpweb.com						
EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2020						
(₹ in Lakhs)						
Sr No.	Particulars	Standalone			Consolidated	
		Quarter ended 30-09-2020	30-09-2019	30-09-2020	30-09-2020	30-09-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Total Income from Operation (Net)	7,509.10	8,894.87	10,673.76	7,515.25	8,884.84
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	112.99	29.90	(632.14)	112.82	33.24
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	112.99	29.90	(632.14)	112.82	33.24
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	90.13	47.67	(472.09)	89.51	49.33
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	151.35	(37.77)	(478.19)	150.36	(37.55)
6	Equity Share Capital	133.33	133.33	133.33	133.33	133.33
7	Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) (Not Annualised)					
	1. Basic : (in ₹)	6.76	3.58	(35.41)	6.71	3.70
	2. Diluted : (in ₹)	6.76	3.58	(35.41)	6.71	3.70

**Notes:**

- The above is an extract of the detailed format of Quarterly/ Half Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Half Year ended Financial Results are available on the Stock Exchange websites www.nseindia.com & www.bseindia.com and on the Company's website (www.grpweb.com).
- The above results have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 11th November, 2020.
- Figures for the previous period are regrouped/reclassified wherever necessary, to make them comparable.

FOR GRP LIMITED  
HARSH R. GANDHI  
JOINT MANAGING DIRECTOR

Place : Mumbai  
Date : 11th November, 2020

